Avadel Pharmaceuticals Plc (AVDL) SEC Filing 8-K Material Event for the period ending Tuesday, October 1, 2019

Avadel Pharmaceuticals Plc

CIK: 1012477 Ticker: AVDL

View differences made from one to another to evaluate Avadel Pharmaceuticals Plc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Avadel Pharmaceuticals Plc.


Assess how Avadel Pharmaceuticals Plc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Avadel Pharmaceuticals Plc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Material Contracts, Statements, Certifications & more

Avadel Pharmaceuticals Plc provided additional information to their SEC Filing as exhibits

Ticker: AVDL
CIK: 1012477
Form Type: 8-K Corporate News
Accession Number: 0000910680-19-000072
Submitted to the SEC: Fri Oct 04 2019 4:13:31 PM EST
Accepted by the SEC: Fri Oct 04 2019
Period: Tuesday, October 1, 2019
Industry: Pharmaceutical Preparations
  1. Event for Officers
  2. Financial Exhibit

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: